Efficacy of Faviprevir in COVID-19 Treatment

• Status: Completed
• Trial end date: 2020-09-28
• Target enrollment: 0
• Participant gender: All

Summary

Faviprevir in COVID-19 treatment

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Chloroquine; Favipiravir

Criteria

Inclusion Criteria:

• Patients with covid 19

Exclusion Criteria:

• Allergy or contraindications to faviprevir